Altogether, as frontal regions were not consistently disproportionally affected by in-vivo and ex-vivo tau pathology in these patients with bvFTD-like phenotypes, these results suggests that tau pathology may not be the main or sole driver of the clinical phenotype in bvAD. The gene discussed is MAPT; the disease is behavioral variant of frontotemporal dementia.